ResearcherState Key Laboratory of Reproductive MedicineNo recent work listed
Xiao Mo
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2021: 2 papers · 2022: 1 paper
Papers 3
- KCNN4-mediated Ca2+/MET/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-021-00688-3↗
- S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. Co-author DOI 10.1007/s10565-020-09574-w↗
- Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progression of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2020.10.039↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hongping Xia · 3 shared papers, 2021–2022 · strength 0.38
- Paper KCNN4-mediated Ca2+/MET/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma. DOI 10.1038/s41401-021-00688-3↗
- Paper Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progressio… DOI 10.1016/j.ygeno.2020.10.039↗
- Paper S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. DOI 10.1007/s10565-020-09574-w↗
- Alaa Abdelatty · 2 shared papers, 2021–2022 · strength 0.25
- Linhua Lan · 2 shared papers, 2021 · strength 0.25
- Paper Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progressio… DOI 10.1016/j.ygeno.2020.10.039↗
- Paper S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. DOI 10.1007/s10565-020-09574-w↗
- Xin Guo · 1 shared paper, 2022 · strength 0.13
- Hongjin Chen · 1 shared paper, 2021 · strength 0.13
- Xiaoming Wang · 1 shared paper, 2021 · strength 0.13
- Dan Fang · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.